# GBS Ventures

> GBS Ventures is a VC fund in Melbourne backing Biotechnology and Health Care. See 41 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Melbourne, Australia
- Total investments: 41
- Last investment: Aug 2024
- Lead investor: 22%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/gbs-venture-partners/
- Website: http://www.gbsventures.com.au

GBS Ventures is a VC fund in Melbourne focused on Biotechnology and Health Care. Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.

## Contacts

5 contacts available for GBS Ventures. Shizune tracks 4 team members at GBS Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/gbs-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.2M–$9M |
| Series B | $8.8M–$35M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 17 | 41% |
| Health Care | 15 | 37% |
| Medical Device | 7 | 17% |
| Medical | 5 | 12% |
| Pharmaceutical | 5 | 12% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 17% |
| Series A | 6 | 15% |
| Funding Round | 6 | 15% |
| Series C | 4 | 10% |
| Series D | 4 | 10% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 39% |
| Australia | 4 | 10% |
| United Kingdom | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ben Gust | Partner | 10 | https://shizune.co/investors/profile/ben-gust |
| Brigitte Smith | Co-Founder & Managing Partner | 14 | https://shizune.co/investors/profile/brigitte-smith |
| George Morstyn | Investment Committee Member | 0 | https://shizune.co/investors/profile/george-morstyn |
| John Mills | Investment Committee Member | 0 | https://shizune.co/investors/profile/john-mills-3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $61M | Series D | Aug 13, 2024 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $40M | Series C | Aug 16, 2022 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $50M | Series C | Mar 17, 2017 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $50M | Series C | Mar 16, 2017 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $12.6M | Series B | Jan 27, 2016 |  |
| Elastagen | Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen hasdeveloped a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK. | $8.8M | Series B | Jan 07, 2016 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $33M | Series B | May 07, 2015 |  |
| Ivantis | Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $25M | Series B | Sep 23, 2014 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $1M | Series E | Sep 03, 2014 |  |
| Spinifex Pharmaceuticals | Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development ofEMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014.Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents. | $45M | Series C | Apr 10, 2014 |  |

10 of 41 investments shown.

## Co-investors
- [Uniseed](https://shizune.co/investors/profile/uniseed-vc) — VC Fund, 8 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 7 deals together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 6 deals together
- [Alloy Ventures](https://shizune.co/investors/profile/alloy-ventures) — VC Fund, 5 deals together
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 5 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)
- [Biotech VC Funds in Australia](https://shizune.co/investors/biotech-vc-funds-australia)
- [Biotechnology VC Funds in Australia](https://shizune.co/investors/biotechnology-vc-funds-australia)
- [Biotechnology Investors in Australia](https://shizune.co/investors/biotechnology-investors-australia)
- [Biotech VC Funds in Oceania](https://shizune.co/investors/biotech-vc-funds-oceania)
- [Health Care VC Funds in Australia](https://shizune.co/investors/health-care-vc-funds-australia)

## FAQ

### What does GBS Ventures invest in?

GBS Ventures invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is GBS Ventures's check size?

GBS Ventures typically joins rounds of $2.2M–$9M at Series A and $8.8M–$35M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds GBS Ventures participates in.

### How do I contact GBS Ventures?

Public channels for GBS Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at GBS Ventures?

The team at GBS Ventures includes Ben Gust (Partner), Brigitte Smith (Co-Founder & Managing Partner) and George Morstyn (Investment Committee Member). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co